Age and Sex Differences in the Prevalence of Specific Comorbidities among Patients with Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma at Diagnosis.

IF 3.3 Q3 ONCOLOGY Cancer research communications Pub Date : 2025-04-01 DOI:10.1158/2767-9764.CRC-24-0517
Xin Yang, Maua Mosha, Dave Bell, Jennifer Dean, Jennifer Mayer, Ernest K Amankwah
{"title":"Age and Sex Differences in the Prevalence of Specific Comorbidities among Patients with Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma at Diagnosis.","authors":"Xin Yang, Maua Mosha, Dave Bell, Jennifer Dean, Jennifer Mayer, Ernest K Amankwah","doi":"10.1158/2767-9764.CRC-24-0517","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>Limited knowledge exists on the prevalence of comorbidity among pediatric patients diagnosed with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL). To determine the prevalence of comorbidities present within 3 months before diagnosis among pediatric patients with ALL/LL and to examine if the prevalence varies by age, biological sex at birth, and race/ethnicity, we analyzed data of patients diagnosed with ALL/LL at ≤21 years of age from January 1, 2005, to June 30, 2020 (n = 5,455), using electronic health records data from the TriNetX Research Network database. Comorbidities examined included pulmonary, cardiac, cerebrovascular, vascular, developmental, immune, metabolic, infectious, genitourinary, digestive, muscle and connective tissue and central and peripheral nervous system conditions. Overall, the prevalence of comorbidity was 34.1% (n = 1,904), with significant differences observed based on sex and race/ethnicity. Females had a higher prevalence at 36.6% compared with males at 33.6% (P = 0.024). Similarly, non-Hispanic White patients had a higher prevalence of 37.5% compared with 33.1% in other racial/ethnic groups (P < 0.001). Analyses of specific comorbidities revealed notable differences in the prevalence of infectious diseases by biological sex at birth (female: 9.7%, male: 7.0%; P < 0.001) and digestive diseases by age at diagnosis (≤10 years: 13.8%, >10 years: 10.4%; P < 0.001). Although the overall prevalence of comorbidity at diagnosis showed minor differences across groups, disparities exist for specific comorbidities with females and younger patients having a higher prevalence of infectious diseases and digestive tract diseases, respectively. Future studies are needed to evaluate if these differences contribute to the disparities in treatment outcomes.</p><p><strong>Significance: </strong>Among pediatric patients with ALL/LL, significant disparities were found for specific comorbidities, particularly among females and younger patients who had higher rates of digestive tract diseases and infectious diseases. These findings are important as comorbidities can be considered in clinical decision-making in the management and treatment of these patients.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"549-555"},"PeriodicalIF":3.3000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11961403/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer research communications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2767-9764.CRC-24-0517","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract: Limited knowledge exists on the prevalence of comorbidity among pediatric patients diagnosed with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL). To determine the prevalence of comorbidities present within 3 months before diagnosis among pediatric patients with ALL/LL and to examine if the prevalence varies by age, biological sex at birth, and race/ethnicity, we analyzed data of patients diagnosed with ALL/LL at ≤21 years of age from January 1, 2005, to June 30, 2020 (n = 5,455), using electronic health records data from the TriNetX Research Network database. Comorbidities examined included pulmonary, cardiac, cerebrovascular, vascular, developmental, immune, metabolic, infectious, genitourinary, digestive, muscle and connective tissue and central and peripheral nervous system conditions. Overall, the prevalence of comorbidity was 34.1% (n = 1,904), with significant differences observed based on sex and race/ethnicity. Females had a higher prevalence at 36.6% compared with males at 33.6% (P = 0.024). Similarly, non-Hispanic White patients had a higher prevalence of 37.5% compared with 33.1% in other racial/ethnic groups (P < 0.001). Analyses of specific comorbidities revealed notable differences in the prevalence of infectious diseases by biological sex at birth (female: 9.7%, male: 7.0%; P < 0.001) and digestive diseases by age at diagnosis (≤10 years: 13.8%, >10 years: 10.4%; P < 0.001). Although the overall prevalence of comorbidity at diagnosis showed minor differences across groups, disparities exist for specific comorbidities with females and younger patients having a higher prevalence of infectious diseases and digestive tract diseases, respectively. Future studies are needed to evaluate if these differences contribute to the disparities in treatment outcomes.

Significance: Among pediatric patients with ALL/LL, significant disparities were found for specific comorbidities, particularly among females and younger patients who had higher rates of digestive tract diseases and infectious diseases. These findings are important as comorbidities can be considered in clinical decision-making in the management and treatment of these patients.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
儿童急性淋巴母细胞白血病和淋巴母细胞淋巴瘤患者诊断时特异性合并症患病率的年龄和性别差异
目前对诊断为急性淋巴细胞白血病(ALL)或淋巴细胞淋巴瘤(LL)的儿科患者合并症的患病率了解有限。确定儿科ALL/LL患者诊断前3个月内共病的患病率,并检查患病率是否因年龄、出生时生物学性别和种族/民族而异。我们分析了2005年1月1日至2020年6月30日≤21岁ALL/LL患者的数据(n=5,455),使用来自TriNetX研究网络数据库的电子健康记录数据。检查的合并症包括肺部、心脏、脑血管、血管、发育、免疫、代谢、感染性、泌尿生殖系统、消化系统、肌肉和结缔组织以及中枢和周围神经系统疾病。总体而言,共病患病率为34.1% (n= 1904),性别和种族/民族之间存在显著差异。女性的患病率为36.6%,高于男性的33.6% (p=0.024)。同样,非西班牙裔白人(NHW)患者的患病率为37.5%,高于其他种族/族裔群体的33.1% (p< 0.001)。具体合并症分析显示,按出生时生理性别划分的传染病患病率(女性:9.7%,男性:7.0%,p< 0.001)和按诊断时年龄划分的消化系统疾病患病率(≤10岁:13.8%,≤10岁:10.4%,p< 0.001)存在显著差异。虽然诊断时合并症的总体患病率在各组之间存在微小差异,但在特定合并症方面存在差异,女性和年轻患者分别具有较高的传染病和消化道疾病患病率。未来的研究需要评估这些差异是否导致了治疗结果的差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
A phase I study of hydroxychloroquine and suba-itraconazole in men with biochemical relapse of prostate cancer (HITMAN-PC): dose escalation results. The KRAS-variant and cetuximab in HPV-positive oropharyngeal cancer - results from the NRG/RTOG 1016 trial. Mechanisms Underlying Cedazuridine-Mediated Enhancement of Oral Decitabine Bioavailability. Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer-Related Lymphedema. ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1